Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Earlier from Chengdu Easton Biopharmaceuticals
- Announcement on Voluntary Disclosure of Iguratimod Tablets Obtaining Drug Registration Certificate
- Announcement on New Recognized Core Technical Personnel
- Announcement on Progress in Capital Increase in Joint-stock Company and Related Party Transactions
- Announcement on Election of Employee Representative Directors for the 4th Board of Directors
- Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Eperisone Hydrochloride Tablets
Later from Chengdu Easton Biopharmaceuticals
- Report for Q3 2025
- Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement
- Announcement on Progress in Completion of Capital Increase to Joint-stock Company and Related Party Transactions
- Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for YLSH003 for Injection and Completion of the 1st Subject Enrollment
- Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site Inspection
Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals